✅ Model Answer:
• Diagnosis: Microvillus inclusion disease (MVID) – also known as congenital microvillus atrophy.
• Evidence: Profuse secretory diarrhea from birth, neutral stool pH (no carbohydrate malabsorption), recurrent dehydration, metabolic acidosis, normal sweat chloride (excludes CF).
• Next step: Genetic testing (MYO5B gene). Requires long-term total parenteral nutrition (TPN). Intestinal transplantation may be needed. Multidisciplinary management with gastroenterology, nutrition, and transplant teams.

✅ Model Answer:
• Gene: MYO5B (myosin VB) located on chromosome 18q21.
• Inheritance: Autosomal recessive.
• Pathophysiology: MYO5B encodes myosin VB, a motor protein involved in vesicle trafficking and microvillar formation in enterocytes. Mutations lead to defective microvillus assembly and intracellular inclusion bodies of microvilli.
• Prevalence: Rare – one of the most common causes of congenital intractable diarrhea.
• Other associated mutations: STX3, STXBP2 (rare).

✅ Model Answer:
• Classic presentation:
- Profuse watery diarrhea: Secretory (does not stop with fasting), often >100 mL/kg/day.
- Onset: Usually in the first few days to weeks of life.
- Severe dehydration: Recurrent episodes.
- Failure to thrive: Inadequate nutrition despite feeding.
- Metabolic acidosis: Due to bicarbonate loss in stool.
- Electrolyte imbalances: Hyponatremia, hypokalemia.
• Other features:
- Neutral stool pH (unlike carbohydrate malabsorption).
- Reducing substances: Negative (no carbohydrate malabsorption).
- Mild steatorrhea.
- Poor growth despite enteral feeding.

✅ Model Answer:
• Small bowel biopsy:
- Light microscopy: Villous atrophy (partial to total), crypt hyperplasia, enterocytes with a "tuff" or "pseudo-stratified" appearance.
- Electron microscopy: Gold standard – shows microvillus inclusion bodies (intracellular vacuoles containing microvilli) and absence or shortening of apical microvilli.
• Genetic testing: MYO5B gene sequencing (confirmatory).
• Other tests:
- Stool pH and reducing substances: To rule out carbohydrate malabsorption.
- Sweat chloride: To rule out CF.
- Fecal elastase: Normal (excludes pancreatic insufficiency).
- Serum electrolytes, blood gas: To assess dehydration and metabolic acidosis.
• Prenatal diagnosis: If family history is known (genetic testing).

✅ Model Answer:
• Total parenteral nutrition (TPN):
- Mainstay of therapy: Provides long-term nutritional support.
- Central venous access: Requires long-term central line (PICC, Broviac, or Port-a-Cath).
- Monitor: Liver function (risk of TPN-associated liver disease).
• Fluid and electrolyte management:
- IV fluids: To correct dehydration and maintain fluid balance.
- Electrolyte supplementation: Sodium, potassium, bicarbonate (as needed).
• Dietary modifications:
- Elemental or amino acid-based formula: May be tried, but often not tolerated.
- Octreotide: May reduce stool output (limited benefit).
• Intestinal transplantation:
- Indication: For TPN failure, severe liver disease, or recurrent line infections.
- Outcome: Survival >80% in specialized centers.
• Multidisciplinary care: Gastroenterology, nutrition, surgery, transplant team.

✅ Model Answer:
• TPN-related:
- TPN-associated liver disease (TALD): Cholestasis, fibrosis, cirrhosis (most common cause of mortality).
- Central line infections: Sepsis, line thrombosis.
- Metabolic bone disease: Osteopenia, fractures.
- Growth failure.
• Intestinal:
- Chronic diarrhea: Despite TPN, some stool output persists.
- Malabsorption: Fat-soluble vitamins, electrolytes.
- Small bowel bacterial overgrowth (SIBO).
- Intestinal failure.
• Other:
- Neurologic: Developmental delay (if chronic dehydration or TPN complications).
- Renal: Nephrocalcinosis (due to electrolyte imbalances).
- Death: Without intestinal transplant, mortality is high in early childhood.

✅ Model Answer:
• Prognosis:
- Historically poor: Many infants die in the first year of life without intestinal transplantation.
- With TPN: Survival improves, but TPN-associated liver disease is a major complication.
- With intestinal transplant: Survival >80% in specialized centers.
- Quality of life: Dependent on TPN and/or transplant; requires lifelong medical care.
• Long-term follow-up:
- Multidisciplinary care: Gastroenterology, hepatology, nutrition, surgery, transplant team.
- Monitor liver function: AST, ALT, GGT, bilirubin, ultrasound.
- Monitor growth: Height, weight, BMI.
- Monitor nutritional status: Fat-soluble vitamins, iron, zinc, electrolytes.
- Monitor for line infections.
- Genetic counseling: Autosomal recessive (25% recurrence risk).

✅ Model Answer:
• Microvillus inclusion disease (MVID):
- Stool: Profuse watery, secretory diarrhea (does not stop with fasting).
- Stool pH: Neutral (~7.0).
- Stool electrolytes: Variable; no specific pattern.
- ABGs: Metabolic acidosis (bicarbonate loss).
- Gene: MYO5B.
- Histology: Microvillus inclusions on EM, villous atrophy.
- Treatment: TPN, intestinal transplant.
• Congenital chloride diarrhea (CCD):
- Stool: Profuse watery, high stool chloride (>90 mmol/L).
- Stool pH: Neutral or alkaline.
- Stool electrolytes: High chloride, low sodium/potassium.
- ABGs: Metabolic alkalosis (due to chloride loss).
- Gene: SLC26A3.
- Histology: Normal villi, no inclusions.
- Treatment: Sodium chloride + potassium supplementation, no TPN needed (if electrolytes are replaced).